Acquired haemophilia A: Two cases

被引:1
|
作者
de Vitry, A. [1 ]
Valois, A. [2 ]
Weinborn, M. [1 ]
Dupuy-de Fonclare, A. -L. [2 ]
Cuny, J. -F. [1 ]
Barbaud, A. [1 ]
Schrnutz, J. -L. [1 ]
机构
[1] CHU, Serv Dermatol, F-54500 Vandoeuvre Les Nancy, France
[2] Hop Instruct Armees Legouest, Serv Dermatol, F-57070 Metz, France
来源
ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE | 2014年 / 141卷 / 6-7期
关键词
Acquired haemophilia A; Bruises; Bleeds; Coagulation; Factor VIII antibody; Blood diseases; FACTOR-VIII; COAGULATION-FACTORS; FACTOR-IX; INHIBITORS; DIAGNOSIS; AUTOANTIBODIES; ANTIBODIES; MANAGEMENT; THERAPY;
D O I
10.1016/j.annder.2014.03.012
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background. - Acquired haemophilia A (AH) is an uncommon bleeding disorder that presents as multiple, disseminated spontaneous subcutaneous bleeds. Diagnosis may be made on the basis of prolonged activated partial thromboplastin time (aPTT). The severity of the disease is associated with the low risk of haemoglobin levels and with potential links with other diseases. Observations. - Two men were hospitalized for extensive and spontaneous subcutaneous hematoma. In both cases, the International Normalized Ratio (INR) was normal, but aPTT was 3 times higher than normal. Autoantibodies against coagulation factor VIII confirmed the diagnosis of AH. The patients received immunomodulatory treatment. In one patient, diffuse large B-cell lymphoma was discovered one year after successful treatment of AH. Discussion. - All may be revealed by areas of bruising, subutaneous haematomas mimicking erythema nodosum, and muscle pain. APTT results alone can prompt the biologist to screen for factor VIII inhibitors. Aside from the risk of fatal bleeding, in half of all cases, the prognosis is determined by associated disorders such as blood dyscrasias, solid tumours, autoimmune diseases, use of certain medicines and pregnancy. After treatment for bleeding complications, therapy focuses on restoring the coagulation time. The aim of immunomodulatory therapy is to stem production of autoantibodies against coagulation factor VIII. Conclusion. - AH must be considered rapidly in order to reduce the risk of bleeding emergencies and to screen for potential related diseases. (C) 2014 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:441 / 445
页数:5
相关论文
共 50 条
  • [21] Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2)
    Knoebl, P.
    Marco, P.
    Baudo, F.
    Collins, P.
    Huth-Kuhne, A.
    Nemes, L.
    Pellegrini, F.
    Tengborn, L.
    Levesque, H.
    Aspoek, G.
    Heistinger, M.
    Knobl, P.
    Makipernaa, A.
    Andre, H.
    Aouba, A.
    Bellucci, Sylvia
    Beurrier, P.
    Borg, J. Y.
    Darnige, L.
    Devignes, J.
    D'Oiron, R.
    Gautier, P.
    Gay, V.
    Girault, S.
    Gruel, Y.
    Guerin, V.
    Hezard, N.
    Khellaf, M.
    Koenig, M.
    Lifermann, F.
    Marlu, R.
    Ninet, Jacques
    Peynet, J.
    Quemeneur, T.
    Rothschild, C.
    Schleinitz, N.
    Sigaud, M.
    Trouillier, S.
    Voisin, S.
    Giebl, A.
    Holstein, K.
    Loreth, R. M.
    Steigerwald, U.
    Tiede, A.
    Theodossiades, G.
    Radvanyi, G.
    Schlammadinger, A.
    Barillari, G.
    Pasca, S.
    Baudo, F.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2012, 10 (04) : 622 - 631
  • [22] Acquired Haemophilia A: A Review of What We Know
    Eva Mingot-Castellano, Maria
    Javier Rodriguez-Martorell, Francisco
    Jose Nunez-Vazquez, Ramiro
    Marco, Pascual
    JOURNAL OF BLOOD MEDICINE, 2022, 13 : 691 - 710
  • [23] Rituximab for eradicating inhibitors in people with acquired haemophilia A
    Remmington, Tracey
    Smith, Sherie
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2021, (08):
  • [24] Rituximab for eradicating inhibitors in people with acquired haemophilia A
    Zeng, Yan
    Zhou, Ruiqing
    Duan, Xin
    Long, Dan
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2016, (07):
  • [25] Cross-reacting recombinant porcine FVIII inhibitors in patients with acquired haemophilia A
    Bowyer, Annette
    Shepherd, Fiona
    Platton, Sean
    Guy, Susan
    Kitchen, Steve
    Maclean, Rhona
    HAEMOPHILIA, 2020, 26 (06) : 1181 - 1186
  • [26] Acquired haemophilia A: Italian Consensus Recommendations on diagnosis, general management and treatment of bleeding
    Coppola, Antonio
    Franchini, Massimo
    Tripodi, Armando
    Santoro, Rita C.
    Castaman, Giancarlo
    Marino, Renato
    Zanon, Ezio
    Santoro, Cristina
    Rivolta, Gianna F.
    Contino, Laura
    De Cristfaro, Raimondo
    Molinari, Angelo C.
    Gressel, Paolo
    Rocino, Angiola
    BLOOD TRANSFUSION, 2022, 20 (03) : 245 - 262
  • [27] Outcome of CARE: a 6-year national registry of acquired haemophilia A in China
    Sun, Boyang
    Xue, Feng
    Feng, Ying
    Sun, Jing
    Yu, Ziqiang
    Hou, Ming
    Zhang, Jingyu
    Zeng, Xiaojing
    Zhao, Yongqiang
    Lian, Shimei
    Huang, Meijuan
    Niu, Ting
    Cui, Zhongguang
    Wu, Jingsheng
    Yang, Renchi
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 187 (05) : 653 - 665
  • [28] Risk factors, treatment and survival rates of late-onset acquired haemophilia A: A cohort study from the Shizuoka Kokuho Database
    Shoji-Asahina, Aya
    Nakatani, Eiji
    Imaichi, Yutaro
    Ohata, Emi
    Oshima, Michiko
    Miyakoshi, Akinori
    Miyake, Hiromu
    Ichikawa, Yoshikazu
    Dote, Hisashi
    Ubukata, Nanako
    Funaki, Daito
    Urano, Tetsumei
    HAEMOPHILIA, 2023, 29 (03) : 799 - 808
  • [29] Acquired haemophilia B: a case report and literature review
    Jedidi, Ines
    Hdiji, Sondes
    Ajmi, Naourez
    Makni, Faiza
    Masmoudi, Sayda
    Elloumi, Moez
    Kallel, Choumous
    ANNALES DE BIOLOGIE CLINIQUE, 2011, 69 (06) : 685 - 688
  • [30] FEIBA in the treatment of acquired haemophilia A: Results from the prospective multicentre French 'FEIBA dans l'hemophilie A acquise' (FEIBHAC) registry
    Borg, J. -Y.
    Negrier, C.
    Durieu, I.
    Dolimier, E.
    Masquelier, A. -M.
    Levesque, H.
    HAEMOPHILIA, 2015, 21 (03) : 330 - 337